Aurrum is one of Australia’s leading residential aged care providers with a portfolio of 1,000 operating and development places in Victoria and New South Wales. Aurrum’s operating model is built on a philosophy of delivering clinical care excellence to our residents whilst offering premium quality accommodation, lifestyle and dining experiences. We have partnered with internationally recognised healthcare alliance PLANETREE, whose model of care is based around person-centred care principles which have been adopted across all our facilities. Our aged care homes are designed and maintained to the highest standards, to create a welcoming environment for the care, comfort and privacy of our residents and their families.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

APOLLOMICS INC., A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY TO BE LISTED ON NASDAQ THROUGH BUSINESS COMBINATION

Apollomics, Inc. | September 15, 2022

news image

Apollomics Inc. a late-stage clinical biopharmaceutical company, and Maxpro Capital Acquisition Corp. announced a definitive agreement for a business combination that would result in Apollomics becoming a publicly traded company on the Nasdaq Global Market. The business combination is expected to close in the first quarter of 2023 and Apollomics is expected to be listed on Nasdaq under the ticker symbol “APLM.” Apollomics’ broad pipeline of drug candidates includ...

Read More

Business Insights

ELLIGO HEALTH RESEARCH® PARTNERS WITH PEOPLES RX

Elligo Health Research | April 21, 2022

news image

Elligo Health Research, the largest healthcare-enabling research organization, announced they are expanding partnerships to include Peoples Rx, an Austin, Texas-based pharmacy chain. “We’re in a unique position at Peoples Rx to help inform more people about how they can participate in clinical research opportunities. Working with Elligo to offer research as healthcare to our customers helps support our mission to empower people to make educated he...

Read More

Business Insights, PHARMA TECH

INNATE PHARMA ANNOUNCES PRECLINICAL DATA PUBLICATION IN NATURE BIOTECHNOLOGY

Innate Pharma | January 17, 2023

news image

On January 16, 2023, Innate Pharma SA announced the publication of preclinical findings demonstrating the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123 in the scientific journal Nature Biotechnology. Innate and Sanofi conducted the experiments, which were published in Nature Biotechnology on January 12, 2023. This study demonstrates that CD64 expression on AML blasts imparts resistance to anti-CD123 antibody-d...

Read More

Pharmacy Market

LILLY AND LYCIA THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP NOVEL LYSOSOMAL TARGETING CHIMERA (LYTAC) DEGRADERS

Eli Lilly and Company | August 25, 2021

news image

Eli Lilly and Company and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology. Lycia uses its next-generation degradation approach to target the untapped extracellular proteome, including cell surface receptors and secreted proteins. The LYTAC p...

Read More
news image

Pharma Tech

APOLLOMICS INC., A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY TO BE LISTED ON NASDAQ THROUGH BUSINESS COMBINATION

Apollomics, Inc. | September 15, 2022

Apollomics Inc. a late-stage clinical biopharmaceutical company, and Maxpro Capital Acquisition Corp. announced a definitive agreement for a business combination that would result in Apollomics becoming a publicly traded company on the Nasdaq Global Market. The business combination is expected to close in the first quarter of 2023 and Apollomics is expected to be listed on Nasdaq under the ticker symbol “APLM.” Apollomics’ broad pipeline of drug candidates includ...

Read More
news image

Business Insights

ELLIGO HEALTH RESEARCH® PARTNERS WITH PEOPLES RX

Elligo Health Research | April 21, 2022

Elligo Health Research, the largest healthcare-enabling research organization, announced they are expanding partnerships to include Peoples Rx, an Austin, Texas-based pharmacy chain. “We’re in a unique position at Peoples Rx to help inform more people about how they can participate in clinical research opportunities. Working with Elligo to offer research as healthcare to our customers helps support our mission to empower people to make educated he...

Read More
news image

Business Insights, PHARMA TECH

INNATE PHARMA ANNOUNCES PRECLINICAL DATA PUBLICATION IN NATURE BIOTECHNOLOGY

Innate Pharma | January 17, 2023

On January 16, 2023, Innate Pharma SA announced the publication of preclinical findings demonstrating the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123 in the scientific journal Nature Biotechnology. Innate and Sanofi conducted the experiments, which were published in Nature Biotechnology on January 12, 2023. This study demonstrates that CD64 expression on AML blasts imparts resistance to anti-CD123 antibody-d...

Read More
news image

Pharmacy Market

LILLY AND LYCIA THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP NOVEL LYSOSOMAL TARGETING CHIMERA (LYTAC) DEGRADERS

Eli Lilly and Company | August 25, 2021

Eli Lilly and Company and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology. Lycia uses its next-generation degradation approach to target the untapped extracellular proteome, including cell surface receptors and secreted proteins. The LYTAC p...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us